Is the Pictorial Blood Loss Assessment Chart (PBAC) score associated with treatment outcome after endometrial ablation for heavy menstrual bleeding? A cohort study
- PMID: 28012272
- DOI: 10.1111/1471-0528.14434
Is the Pictorial Blood Loss Assessment Chart (PBAC) score associated with treatment outcome after endometrial ablation for heavy menstrual bleeding? A cohort study
Abstract
Objective: The Pictorial Blood Loss Assessment Chart (PBAC) is a validated tool that is used to diagnose heavy menstrual bleeding (HMB). Knowledge of the effect of its score and its relationship with outcome could have implications for using the PBAC as an outcome measurement in future HMB studies, and as a tool to evaluate the treatment effect in research and clinical practice. Our aim was to relate PBAC scores to other measures of success after endometrial ablation for HMB.
Design: Analysis of individual patient data (IPD) of randomised controlled trials studying women with HMB.
Setting: Women with HMB consulting their gynecologists.
Population or sample: Individual patient data (IPD) of randomised controlled trials studying women with HMB.
Methods: We included studies if they had studied second-generation endometrial ablation techniques and had collected PBAC scores for both baseline and follow-up. The effectiveness of treatment was scored as satisfaction or re-intervention (yes/no) 12 months after treatment. We related these outcomes to the PBAC score at 12 months after treatment, and to PBAC decrease between baseline and 12 months of follow-up.
Results: We studied data for 900 patients included in nine studies. The median PBAC score at 12 months was 7 (0-2500). The overall satisfaction rate was 89% and the overall re-intervention rate was 7.2%. A clear association was found between absolute PBAC score at the 12-month follow-up and satisfaction (odds ratio, OR 0.16; 95% confidence interval, 95% CI 0.11-0.24) and surgical re-intervention (OR 2.3, 95% CI 1.8-2.8). A change in PBAC score was also associated with satisfaction (OR 2.0, 95% CI 1.7-2.3) and surgical re-intervention (OR 0.69, 95% CI 0.63-0.75). Both the absolute PBAC scores and the changes in score show high accuracy for both treatment outcomes.
Conclusions: PBAC scores at 12 months after treatment are significantly associated with satisfaction and re-intervention rates. We propose to use the PBAC in research as a primary end point in studies on HMB, and in clinical practice as a measure to assess the effectiveness of treatment.
Tweetable abstract: PBAC scores 12 months after treatment are significantly associated with satisfaction and reintervention rates.
Keywords: Pictorial Blood Loss Assessment Chart; endometrial ablation; heavy menstrual bleeding.
© 2016 Royal College of Obstetricians and Gynaecologists.
Similar articles
-
Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.Cochrane Database Syst Rev. 2019 Aug 29;8(8):CD000329. doi: 10.1002/14651858.CD000329.pub3. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Feb 23;2:CD000329. doi: 10.1002/14651858.CD000329.pub4. PMID: 31463964 Free PMC article. Updated.
-
Endometrial resection and ablation techniques for heavy menstrual bleeding.Cochrane Database Syst Rev. 2019 Jan 22;1(1):CD001501. doi: 10.1002/14651858.CD001501.pub5. Cochrane Database Syst Rev. 2019. PMID: 30667064 Free PMC article.
-
A 52-mg levonorgestrel-releasing intrauterine system vs bipolar radiofrequency nonresectoscopic endometrial ablation in women with heavy menstrual bleeding: long-term follow-up of a multicenter randomized controlled trial.Am J Obstet Gynecol. 2024 May;230(5):542.e1-542.e10. doi: 10.1016/j.ajog.2024.01.016. Epub 2024 Jan 26. Am J Obstet Gynecol. 2024. PMID: 38280433 Clinical Trial.
-
Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding.Am J Obstet Gynecol. 2021 Feb;224(2):187.e1-187.e10. doi: 10.1016/j.ajog.2020.08.016. Epub 2020 Aug 12. Am J Obstet Gynecol. 2021. PMID: 32795428 Clinical Trial.
-
The levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding: a cost-effectiveness analysis.BJOG. 2021 Nov;128(12):2003-2011. doi: 10.1111/1471-0528.16836. Epub 2021 Jul 27. BJOG. 2021. PMID: 34245652 Free PMC article. Clinical Trial.
Cited by
-
Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.J Blood Med. 2021 Jun 11;12:449-463. doi: 10.2147/JBM.S271744. eCollection 2021. J Blood Med. 2021. PMID: 34149292 Free PMC article. Review.
-
ISUOG Consensus Statement on rationalization of early-pregnancy care and provision of ultrasonography in context of SARS-CoV-2.Ultrasound Obstet Gynecol. 2020 Jun;55(6):871-878. doi: 10.1002/uog.22046. Ultrasound Obstet Gynecol. 2020. PMID: 32267981 Free PMC article. No abstract available.
-
Application of modified subtotal resection of adenomyosis combined with LNG-IUS and GnRH-a sequential therapy in severe adenomyosis: A case series.Front Surg. 2022 Aug 18;9:914725. doi: 10.3389/fsurg.2022.914725. eCollection 2022. Front Surg. 2022. PMID: 36061067 Free PMC article.
-
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.Res Pract Thromb Haemost. 2020 Dec 18;5(1):223-230. doi: 10.1002/rth2.12471. eCollection 2021 Jan. Res Pract Thromb Haemost. 2020. PMID: 33537547 Free PMC article.
-
To Study the Efficacy and Safety of Diosmin with Tranexamic Acid and Mefenamic Acid Versus only Tranexamic Acid and Mefenamic Acid in Medical Management of Abnormal Uterine Bleeding: A Randomized Controlled Trial.J Midlife Health. 2023 Apr-Jun;14(2):87-93. doi: 10.4103/jmh.jmh_253_22. Epub 2023 Sep 18. J Midlife Health. 2023. PMID: 38029032 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical